Object Oriented Programming Untuk Sistem Informasi Pencatatan Hutang Dalam Pengadaan Obat Pada Rsud X

In the drug procurement process, there is no specific record of debt by the Pharmacy section or by the Finance Sector. The records that are trying to be done are like payment receipts from the Finance Sector paying invoices from the drug industry that have provided drugs to the Pharmacy Section. So that the financial sector in managing debt as well as in recognizing debt and the maturity of debt payments of each supplier. With these obstacles, the RSUD requires an Information System for Recording Debts in Procurement of Auxiliary Drugs for the Pharmaceutical Sector and the Financial Sector in recording Debts, especially in the procurement of Drugs. This data system uses object-oriented programming with a SQL Server database to create an information system that can speed up the forest recording process in drug procurement Keywords: Object Oriented Programing, hutang, RSUD

Evaluation of Drug Procurement with the E-Phurchasing System on the Availability of Drugs at the Pharmacy Installation of the Central Aceh Regency Health Office 2021

The purpose of the study was to evaluate drug procurement with the E-Purchasing system on the availability of drugs at the Pharmacy Installation of the Health Office of Central Aceh Regency. The research design used qualitative research methods through in-depth interviews accompanied by direct observation (observation). Informants of the Head of the Health Office, the Head of the Pharmacy Installation of the Health Office, the Planning and Finance Subdivision of the Health Office, the drug management officer at the Health Office and the health center drug management officer were 2 people. Data analysis is presented in the form of a text (content analysis). The results of the research on the availability of drugs at the Pharmacy Installation of the Aceh Tengan District Health Office have not been maximized, the process of ordering drugs by E-purchasing and Non-E-purchasing is in accordance with PMK No. 63 of 2014, but the fulfillment time is not in accordance with the 2014 Pharmaceutical Service Standards. The budget provided for the drug procurement process by e-purchasing is not sufficient. The conclusion of this study is that the availability of drugs in the Pharmacy Installation of the District Health Office of Central Aceh Regency has not been maximized. This drug vacancy is caused by the number of drugs that are not all realized, the time of drug delivery by the distributor.

Impact of Volume-Based Drug Procurement Policy on Drug Use Structure of Chinese Public Medical Institutions: A Difference-in-Difference Analysis of Nine Pilot Cities and Twelve Non-pilot Provinces

Background In 2019, the Chinese government implemented the first round pilot of volume-based drug procurement in 4 municipalities and 7 sub-provincial cities, i.e. “4+7” policy. This study evaluated the impact of “4+7” policy on the use structure of policy-related drugs. Methods Data of China Drug Supply Information Platform (CDSIP) database was used, covering 18,636 public medical institutions from 9 pilot cities and 12 non-pilot provinces in mainland China. “4+7” policy-related drugs were selected as study samples, including 25 drugs in the “4+7” procurement List and 83 alternative drugs that have an alternative relationship with “4+7” List drugs. “4+7” List drugs were divided into bid-winning and bid-non-winning products. Drug Structure Index (DSI) was employed as the outcome variable, and higher DSI refers to the use proportion of higher-DDDc (Defined Daily Drug cost) drugs increased. Difference-in-difference (DID) method was employed to estimate the net effect of “4+7” policy. Results After policy intervention, the DSI of bid-winning drugs significantly decreased (β=-0.233, p<0.0001), while non-winning drugs (β = 0.177, p<0.001) and “4+7” List drugs (β = 0.050, p<0.01) increased. No significant change was found for the overall DSI of alternative drugs (β = 0.013, p>0.05), while a remarkable increase was found in primary healthcare settings (β = 0.033, p<0.05). In three post-“4+7” periods, the increments of DSI for non-winning products were 17.54% (period 1), 18.35% (period 2), and 19.66% (period 3). The DSI of “4+7” List drugs significantly increased in post-“4+7” period 2 and 3 (all p-values<0.05). Conclusions The use proportion of higher-DDDc bid-winning drugs significantly decreased after policy intervention. However, among drugs not involved by NCDP policy, the use proportion of higher-DDDc drugs significantly increased after policy intervention, moreover, the increment was more pronounced at the later periods of policy implementation. The clinical use monitoring and the physician’s prescription behavior supervision should be strengthened.

The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis

Background In 2019, Chinese government launched a nationwide volume-based drug procurement aiming at reducing drug prices and saving drug costs through economies of scale, which aroused widespread attention. The first round of the policy pilot was implemented in 4 municipalities and 7 sub-provincial cities, referred to as “4 + 7” policy. In the “4 + 7” policy, 7 antihypertensive drugs were included. This study was conducted to evaluate the impact of “4 + 7” policy on the use of policy-related antihypertensive drugs. Method This study applied single-group Interrupted Time Series (ITS) design. We used drug purchasing data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. Antihypertensive drugs related to “4 + 7” policy were selected as study samples, including 7 drugs in the “4 + 7” List and 17 alternative drugs. Alternative drugs refer to antihypertensive drugs that have an alternative relationship with “4 + 7” List drugs in clinical use and have not yet been covered by the policy. “4 + 7” List drugs were then divided into bid-winning and bid-non-winning products according to the bidding results. Purchase volume, expenditures, and daily costs were selected as outcome variables, and were measured using Defined Daily Doses (DDDs), Chinese Yuan (CNY), and Defined Daily Drug cost (DDDc). Results After “4 + 7” policy intervention, the procurement volume of bid-winning antihypertensive drugs significantly increased (3.12 million DDD, 95 % CI = 2.14 to 4.10, p < 0.001), while the volume of non-winning drugs decreased (-2.33 million DDD, 95 % CI= -2.83 to -1.82, p < 0.01). The use proportion of bid-winning antihypertensive drugs increased from 12.31 to 87.74 % after policy intervention. The overall costs of the seven “4 + 7” List antihypertensive drugs significantly declined (-5.96 million CNY, 95 % CI= -7.87 to -4.04, p < 0.001) after policy intervention, with an absolute reduction of 36.37 million CNY compared with the pre-“4 + 7” period. The DDDc of bid-winning antihypertensive drugs significantly decreased (-1.30 CNY, 95 % CI= -1.43 to -1.18, p < 0.001), while the DDDc of non-winning (0.28 CNY, 95 % CI = 0.11 to 0.46, p < 0.01) and alternative (0.14 CNY, 95 % CI = 0.03 to 0.25, p < 0.05) antihypertensive drugs increased markedly. Conclusions The implementation of “4 + 7” policy promoted the drug use hypertensive patients gradually concentrated on the quality-guaranteed bid-winning drugs, which might be conducive to improve the overall quality level of drug use of Chinese hypertensive patients. Besides, a preliminary positive policy effect of price cut and cost-saving was observed in the antihypertensive drug category. In the future, price monitoring and drug use management regarding policy-related drugs should also be strengthened.

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

Background The Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China in 2019. This study aims to examine the impact of “4 + 7” policy on the price of policy-related drugs. Methods This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. “4 + 7” policy-related drugs were selected as study samples, including 25 drugs in the “4 + 7” procurement list and 57 alternative drugs that have an alternative relationship with “4 + 7” List drugs in clinical use. “4 + 7” List drugs were then divided into bid-winning and bid-non-winning products according to the bidding results. Single-group Interruption Time Series (ITS) analysis was adopted to examine the change of Drug Price Index (DPI) for policy-related drugs. Results The ITS analysis showed that the DPI of winning (− 0.183 per month, p < 0.0001) and non-winning (− 0.034 per month, p = 0.046) products significantly decreased after the implementation of “4 + 7” policy. No significant difference was found for the immediate change of DPI for alternative drugs (p = 0.537), while a significant decrease in change trend was detected in the post-“4 + 7” policy period (− 0.003 per month, p = 0.014). The DPI of the overall policy-related drugs significantly decreased (− 0.261 per month, p < 0.0001) after “4 + 7” policy. Conclusions These findings indicate that the price behavior of pharmaceutical enterprises changed under NCDP policy, while the price linkage effect is still limited. It is necessary to further expand the scope of centralized purchased drugs and strengthen the monitoring of related drugs regarding price change and consumption structure.

Analysis Delay Budget Absorption the Work Unit of KPPN Singaraja

At the end of 2019, precisely in December, a new Covid-19 virus outbreak was discovered in Wuhan, China. The emergence of this virus was first detected in Indonesia in March 2020. Since this virus first appeared in Indonesia, the government immediately issued a new policy, namely refocusing and reallocating the APBN expenditure budget, as well as accelerating the procurement of goods/services for health facilities, such as drug procurement. - Medicines and medical devices. As a result of this refocusing and reallocation of the APBN budget, the absorption of the expenditure budget has accumulated at the end of the year. This accumulation of budget absorption tends to be low at the beginning of the year and soaring high at the end of the year. The purpose of this study is to determine the factors that cause the accumulation of budget absorption due to Covid-19. This type of research is descriptive qualitative with transcendental phenomenology. The data analysis technique used is Miles & Huberman. The data in this study were obtained through literature study, document analysis, observation, and interviews. The results of this study indicate that changes in the budget, human resources, and procurement of goods/services cause the accumulation of budget absorption.

Implementation and Impact of National Centralized Drug Procurement Policy in China: Evidence from the National Drug Procurement Database

Background Chinese government implemented the first round of National Centralized Drug Procurement pilot in 4 municipalities and 7 sub-provincial cities in 2019, so called "4 + 7" policy. This study evaluated the implementation and impact of “4 + 7” policy. Methods This study used drug purchase data from China Drug Supply Information Platform (CDSIP) database. “4 + 7” policy-related drugs were selected as study samples, including 25 drugs in the “4 + 7” List and 92 alternative drugs that have an alternative relationship with “4 + 7” List drugs in clinical use. “4 + 7” List drugs were divided into bid-winning and non-winning products. We applied Defined Daily Doses (DDDs), DDDs per 1000 inhabitants per day (DID), purchase expenditures, and Defined Daily Drug cost (DDDc) as outcome variables. Interrupted time-series was adopted to quantity policy effect. Results As of December 2019, the completion rate of overall bid-winning drugs in 9 pilot cities reached 154.40%, and the completion rate of 25 bid-winning drugs ranged between 74.77% and 477.75%. After policy intervention, the DID of bid-winning drugs, “4 + 7” List drugs, alterative drugs, as well as the overall policy-related drugs increased by 545.18%, 14.03%, 12.21%, and 13.04% in pilot cities. Bid-winning drugs significantly increased 132.84 million DDDs (p < 0.001) in volume and 48.95 million CNY (p < 0.05) in expenditures, and dropped 6.35 CNY (p < 0.001) in DDDc. The volume proportion of bid-winning products increased from 12.67–71.66%. The DDDc of non-winning drugs increased 0.94 CNY (p < 0.001). Overall, the DDDc of policy-related drugs dropped 1.38 CNY (p < 0.001), and the expenditures decreased 634.68 million CNY (p < 0.001). Conclusion An overall satisfying implementation progress of “4 + 7” policy was observed in pilot cities. The policy alleviated the medication burdens of patients, which is supported by the significant reduction in DDDc and costs of policy-related drugs. The accessibility and consumption of policy-related drugs improved. However, monitoring regarding the clinical use of policy-related drugs will still be necessary in the future.

The impact of National Centralized Drug Procurement policy on the use of policy-related original and generic drugs in public medical institutions in China: A difference-in-difference analysis based on national database

Objective: To evaluate the impact of the first round of the National Centralized Drug Procurement (NCDP) pilot (referred to as "4+7" policy) on the use of policy-related original and generic drugs. Methods: Drug purchase data from the China Drug Supply Information Platform (CDSIP) database were used, involving nine "4+7" pilot cities and 12 non-pilot provinces in China. "4+7" policy-related drugs were included, which consisted of 25 "4+7" List drugs and 97 alternative drugs that have an alternative relationship with "4+7" List drugs in clinical use. "4+7" List drugs were divided into bid-winning and non-winning products according to the bidding results. Purchase volume, purchase expenditures, daily costs were selected as outcome variables, and were measured using Defined Daily Doses (DDDs), Chinese Yuan (CNY), and Defined Daily Drug cost (DDDc), respectively. Difference-in-Difference (DID) method was employed to estimate the net effect of policy impact. Results: After policy intervention, the DDDs of original drugs among "4+7" List drugs significantly reduced by 124.59%, while generic drugs increased by 52.12% (all p-values <0.01). 17.08% of the original drugs in DDDs were substituted by generic drugs. Prominent reductions of 121.69% and 80.54% were observed in the expenditure of original and generic drugs, with a total cost-saving of 5036.78 million CNY for "4+7" List drugs. The DDDc of bid-winning original and generic drugs, as well as non-winning original drugs, significantly decreased by 33.20%, 75.74%, and 5.35% (all p-values <0.01), while the DDDc of non-winning generic drugs significantly increased by 73.66% (p<0.001). The use proportion of bid-winning products and non-winning original drugs raised prominently from 39.66% to 91.93% Conclusions: "4+7" policy promoted the substitution use of generic drugs against original drugs, which conducive to drug costs saving. The overall quality level of drug use of public medical institutions significantly increased after "4+7" policy, especially in primary medical institutions.